Income Investors Should Know That Innovita Biological Technology Co., Ltd. (SHSE:688253) Goes Ex-Dividend Soon

Readers hoping to buy Innovita Biological Technology Co., Ltd. (SHSE:688253) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date is

Simply Wall StJun 1 21:04 ET

Innote (688253.SH) will pay 0.4 yuan per share in 2023. The stock registration date is June 5

Innote (688253.SH) issued an announcement. The company will implement the 2023 annual equity distribution, and each share will be distributed to discover...

Zhitong FinanceMay 28 05:58 ET

Innovita Biological Technology's (SHSE:688253) Strong Earnings Are Of Good Quality

Innovita Biological Technology Co., Ltd.'s (SHSE:688253) strong earnings report was rewarded with a positive stock price move. We have done some analysis, and we found several positive factors beyond

Simply Wall StApr 25 20:26 ET

Innote (688253.SH) announced its 2023 annual results, with net profit of 174 million yuan, an increase of 15.44%

Innote (688253.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 4...

Zhitong FinanceApr 15 04:05 ET

Innovita Biological Technology Co., Ltd.'s (SHSE:688253) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Most readers would already be aware that Innovita Biological Technology's (SHSE:688253) stock increased significantly by 47% over the past three months. We wonder if and what role the company's fina

Simply Wall StMar 28 00:56 ET

Innote (688253.SH): Key marketing products this year are still chromatographic products, and Jiulian products are dominated by steady growth

Gelonghui March 5 | Innote (688253.SH) disclosed an investor relations activity record table showing that this year's key marketing products are still chromatographic products, and Jiulian products are mainly growing steadily. Molecular products are expected to be launched soon. The products are positioned as routine testing items in hospitalization scenarios, and no separate equipment is required. As molecular platform technology matures, molecular POCT products are also the company's long-term plans.

Gelonghui FinanceMar 4 18:50 ET